Senhwa Biosciences, a clinical-stage biopharmaceutical company based in Taiwan, has entered a partnership with a global investment group to accelerate its artificial intelligence-related drug development. According to an April 14 report, Senhwa Biosciences has signed a Memorandum of Understanding (MOU)…
Related Posts
Truemarkets, Base L2’s cousin of Polymarket, is officially launched
A new prediction market platform Truemarkets has finally launched after raising over $4 million through its public Oracle…
Chainlink ditches Ethereum PoW forks for PoS after The Merge
The Chainlink protocol will continue operations on Ethereum after the upcoming Merge to the proof-of-stake consensus layer.
Popular NFT collections take massive price hit in 2023
Investments in top NFT projects such as Doodles, Invisible Friends, Moonbirds and Goblintown have lost up to 95%…